ArticleCureus2025
Prolonged Proton Pump Inhibitor Use and Electrolyte Abnormalities: A Case Presentation and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Medication-safety burden of omeprazole in psychiatric inpatients: A retrospective cross-sectional study.The Journal of international medical research · 2026Article
- The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation.NPJ biofilms and microbiomes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are utilized in the treatment of acid-related gastrointestinal diseases, such as gastroesophageal reflux disease (GERD) and peptic ulcers. Like any drug, they can cause side effects, some of which are observed during the clinical trial phase, while others become apparent during post-market surveillance. We present the case of a 68-year-old Caucasian female patient who had been taking a PPI (esomeprazole 40 mg twice daily) for over 10 years and presented to the Emergency Department (ED) with decreased magnesium levels (<0.5 mg/dL), hypokalemia (3.1 mmol/L), and hypocalcemia (<6.1 mg/dL), with no significant symptoms on initial presentation. The patient was treated with electrolyte repletion, and her medication was switched from omeprazole to famotidine upon stabilization of her electrolytes. She was discharged home with a follow-up appointment to further evaluate for channelopathies with Nephrology. The implications of this adverse effect underscore the importance of increased awareness among both healthcare providers and patients. Clinicians should consider the risk of PPI-induced hypomagnesemia, especially in patients with risk factors, and regularly monitor magnesium levels in individuals on long-term PPI therapy. Patients should be educated about the potential side effects of PPIs, including hypomagnesemia, and encouraged to report any concerning symptoms promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.